PRQR ProQR Therapeutics

ProQR Appoints Naveed Shams, MD, PhD as Chief Scientific Officer

ProQR Appoints Naveed Shams, MD, PhD as Chief Scientific Officer
EN
05/10/2020

Underlying

PRQRProQR Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ProQR Therapeutics

 PRESS RELEASE
Free
PRQR ProQR Therapeut...

ProQR Announces Third Quarter 2025 Operating and Financial Results

ProQR Announces Third Quarter 2025 Operating and Financial Results Received CTA authorization for Phase 1 trial of lead program AX-0810, targeting NTCP for cholestatic diseasesInitiating Phase 1 study of AX-0810 in healthy volunteers, with initial safety, tolerability, and PK data from Cohort 1 expected by year-end, and target engagement data from all cohorts in H1 2026€ 106.9 million cash and cash equivalents as of end Q3 – providing runway into mid-2027 LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) --  ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company ...

November 6, 2025 1 EN
 PRESS RELEASE
Free
PRQR ProQR Therapeut...

ProQR Receives CTA Authorization for AX-0810 and Announces Virtual Inv...

ProQR Receives CTA Authorization for AX-0810 and Announces Virtual Investor and Analyst Event on November 3, 2025 LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that following review under the new European Medicines Agency (EMA) centralized review process, the Central Committee on Research Involving Human Subjects (CCMO) has authorized ProQR’s Clinical Trial A...

October 20, 2025 1 EN
 PRESS RELEASE
Free
PRQR ProQR Therapeut...

ProQR to Participate in Upcoming Investor Conferences in October 2025

ProQR to Participate in Upcoming Investor Conferences in October 2025 LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary ADAR-mediated Axiomer™ RNA editing technology platform, today announced that company management will participate in the following upcoming investor conferences:  H.C. Wainwright Genetic Medicines Virtual Conference – October 14-15, 2025Presentation available on demand beginning October 14 at 7:00 am E...

October 13, 2025 1 EN
 PRESS RELEASE
Free
PRQR ProQR Therapeut...

ProQR Announces Second Quarter 2025 Operating and Financial Results

ProQR Announces Second Quarter 2025 Operating and Financial Results Submitted CTA for lead program AX-0810, targeting NTCP for cholestatic diseasesAdvancing AX-2402 program toward clinical candidate selection, targeting MECP2 (R270X) for Rett SyndromeHosting fall Analyst and Investor Event (virtual), featuring detailed AX-0810 Phase 1 trial design and 2025 data expectations, plus updates across differentiated liver and CNS pipeline€ 119.8 million cash and cash equivalents as of end Q2 – providing runway into mid-2027, not including additional potential milestones from Lilly partnership LEI...

August 7, 2025 1 EN
 PRESS RELEASE
Free
PRQR ProQR Therapeut...

ProQR Announces Upcoming Presentation at RNA Editing Summit

ProQR Announces Upcoming Presentation at RNA Editing Summit LEIDEN, Netherlands & CAMBRIDGE, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that it will participate in the RNA Editing Summit taking place July 29-31, 2025, in Boston, MA. “We recently achieved a key milestone with the submission of the CTA for AX-0810, targeting NTCP for cholestatic diseases, and we’re building on this momentum ...

July 28, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch